7 U.S. men actively MANAGED for BPH 12M All numbers are approximate. Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015 Oct;22 Suppl 1:1-6. Data on File, PROCEPT BioRobotics Total surgeries based on 2019 market data, representing pre-pandemic surgeries PHARMACEUTICAL FALLOUT C o p y r i g h t 2 0 2 3 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . REAL-TIME, MULTI-DIMENSIONAL VISUALIZATION OF THE EN ...

PROCEPT BioRobotics Corporation. (NASDAQ:PRCT) Q3 2023 Earnings Conference Call November 1, 2023 6:00 PM ET Company Participants Matt Bacso - VP, IR and Business Operations Reza Zadno - President and CEO Kevin Waters - EVP and CFO Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Richard Newitter - Truist Securities Brandon Vasquez - William Blair Nathan Treybeck - Wells Fargo Mike Kratky - Leerink Partners Operator Good day and welcome to ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Matt Bacso - VP, IR and Business Operations Reza Zadno - President and CEO Kevin Waters - EVP and CFO Conference Call Participants Craig Bijou - Bank of America Securities Joshua Jennings - TD Cowen Matthew Mishan - KeyBanc Richard Newitter - Truist Securities. Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Nathan Treybeck - Wells Fargo Brandon Vazquez - William Blair Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition peri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) | Delaware | | | 26-0199180 | | --- | --- | -- ...

Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno - President and CEO Kevin Waters - EVP and CFO Matt Bacso - VP, IR and Business Operations Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - Cowen Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Richard Newitter - Truist Nathan Treybeck - Wells Fargo Matthew Mishan - ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Matt Bacso - Vice President-Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Senior Vice President and Chief Financial Office Conference Call Participants Joshua Jennings - Cowen Craig Bijou - Bank of America Chris Pasquale - Nephron Richard Newitter - Truist Neil Chatterji - B. Riley Nathan Treybeck - Wells Fargo Matthew Mishan - KeyBanc Ryan Zimmerman - BTIG ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-04321 ___________________ ...

1 VISION: THE BPH TREATMENT OF CHOICE FOR ALL PROSTATES November 2022 C o p y r i g h t 2 0 2 2 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipates," "believes," "expects," "intends," "projects, ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q3 2022 Earnings Call Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Bacso – Vice President-Investor Relations Reza Zadno – Chief Executive Officer Kevin Waters – Senior Vice President and Chief Financial Office Conference Call Participants Craig Bijou – BofA Securities Nathan Treybeck – Wells Fargo Richard Newitter – Truist Securities Ryan Zimmerman – BTIG Neil Chatterji – B. Riley Matthew Mishan – KeyBanc Philip Coover – Goldman Sachs Jo ...